KFC
ALBO

Klingenstein Fields & Co’s Albireo Pharma Inc ALBO Stock Holding History

Klingenstein Fields & Co’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-2,740
Closed -$344K – 327
2013
Q2 		$344K Buy
+2,740
New +$285K 0.01% 247

Other funds holding ALBO

AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Klingenstein Fields & Co's ALBO Position: Q3 2013 in Review

Klingenstein Fields & Co sold out of Albireo Pharma Inc (ALBO) in Q3 2013, closing a stake of 2,740 shares — an estimated $344K sold.

Klingenstein Fields & Co first reported a position in ALBO in Q2 2013 and held it in 1 quarter. The position peaked at $344K in Q2 2013. 41 funds tracked by Wall St. Rank hold ALBO as of Q3 2013.

  • Klingenstein Fields & Co reported no remaining Albireo Pharma Inc position as of Q3 2013 after selling out during the quarter.
  • Klingenstein Fields & Co sold 2,740 Albireo Pharma Inc shares in Q3 2013, an estimated $344K.
  • Klingenstein Fields & Co first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 1 quarter.
  • Klingenstein Fields & Co's Albireo Pharma Inc position peaked at $344K in Q2 2013.
  • 41 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q3 2013.

Based on Klingenstein Fields & Co's 13F filing for Q3 2013, filed 4 Nov 2013.